A Form 4 filed on August 12, 2026 discloses that Charles S. Fuchs, President of R&D at Erasca, Inc. (NASDAQ:ERAS), was granted stock options covering 1,300,000 shares of common stock on August 10, 2026, in connection with his commencement of employment.
Key Highlights
- Option grant size: 1,300,000 shares of common stock underlying a stock option award granted on August 10, 2026.
- Exercise price: $18.12 per share, with a price of $0 for the derivative security itself.
- Vesting schedule: 25% vests on the first anniversary of the grant date; the remaining 75% vests in 36 substantially equal monthly installments thereafter.
- Grant split: 21,480 shares were granted under the 2021 Incentive Award Plan; 1,278,520 shares were granted as a nonqualified stock option under the 2026 Employment Inducement Incentive Award Plan.
- Expiration date: The option expires on August 9, 2036.
- Reporting person role: Charles S. Fuchs is identified as an officer with the title President, R&D.
Erasca Grants Inducement Option Award to Newly Hired President of R&D
According to the filing, Charles S. Fuchs received a stock option to purchase 1,300,000 shares of Erasca, Inc. common stock at an exercise price of $18.12 per share. The award was granted on August 10, 2026, and the filing states it was made "in connection with the Reporting Person's commencement of employment," indicating this is an inducement grant tied to his joining the company.
The filing discloses that the total award is split across two equity plans. Of the 1,300,000 shares, 21,480 were granted under the issuer's 2021 Incentive Award Plan, with a portion of those intended to qualify as an incentive stock option under Section 422 of the Internal Revenue Code "to the extent permitted by law." The remaining 1,278,520 shares were granted as a nonqualified stock option under the issuer's 2026 Employment Inducement Incentive Award Plan. Following the transaction, Fuchs beneficially owns 1,300,000 derivative securities directly.
The option vests subject to Fuchs's continued service with the issuer through each applicable vesting date. The first tranche of 25% vests on the first anniversary of the August 10, 2026 grant date, with the date exercisable listed as August 10, 2027. The remaining 75% vests in 36 substantially equal monthly installments after that anniversary. The option has an expiration date of August 9, 2036. The filing was signed by Ebun S. Garner as attorney-in-fact on August 12, 2026.
What Was Disclosed
The Form 4 reports a single acquisition transaction: a stock option grant of 1,300,000 shares to Charles S. Fuchs, President of R&D at Erasca, Inc., at an exercise price of $18.12, granted upon his commencement of employment and expiring August 9, 2036.




Please wait processing your request...